TNFRSF10B and melanoma: Nonetheless, ratio signatures may not be needed when single genes are strong predictors of drug response (e.g. vemurafenib response in BRAFV600E melanoma) and thus may be most useful when the drug target, like DR5, is not an oncogenic driver or requires activation of forward signaling response.